Nasdaq: **SXTP**

Market Data

60 Degrees Pharmaceuticals

Nasdaq: **SXTP**

Fiscal Year	Dec 31
Recent Price[1]	$1.80
Market Cap[1]	$5.8M
Shares Out.[1]	4.10M
Float[1]	3.99M
Avg. Vol. (90-day)[1]	429,063
Revenue (ttm)[2]	$1.0M
Cash (mrq)[2]	$2.0M

[1] As of October 14, 2025
[2] As of June 30, 2025; does not include impact of $10M July 2025 offering

60degreespharma.com

Company Overview

60 Degrees Pharmaceuticals (60P) is a growth-oriented biotechnology company developing new therapies for vector-borne diseases. The Company markets the FDA-approved antimalarial ARAKODA® (tafenoquine) and is advancing tafenoquine into new indications, including babesiosis, a tick-borne infection with no approved treatments. In October 2025, 60P reported the first patient in its relapsing babesiosis study tested negative for infection, submitted a Breakthrough Therapy Designation request, and plans an FDA Type B meeting in early 2026 to discuss a supplementary New Drug Application.

Investment Highlights

ARAKODA® (tafenoquine) – Commercially Launched Antimalarial

- FDA-approved safe, long-acting, mechanistically differentiated anti-malarial, co-developed with U.S. Army
- 1,100+ patient exposures in 8+ published trials
- Commercially available in U.S. via network of major national distributors
- New 8-count bottle format launched June 2025 to expand market potential

Advancing Tafenoquine into Babesiosis – a Significant Unmet Need

- No FDA-approved treatments currently exist for babesiosis
- First patient in relapsing babesiosis study tested negative for infection using the most sensitive FDA-licensed assay available
- Study designed to confirm high cure rates in immunosuppressed patients with relapsing disease
- Remaining patients expected to complete study between January-October 2026

Clear Regulatory Pathway and Growing Momentum

- Breakthrough Therapy Designation request submitted to the FDA (October 2025)
- Type B meeting planned with FDA in early 2026 to define requirements for a supplementary New Drug Application (sNDA)
- Data from three tafenoquine babesiosis studies to support planned sNDA submission in 2026

Large and Growing Market Opportunity

- U.S. babesiosis market estimated at ~380,000 addressable patients annually
- Represents ~$245M in potential peak annual sales and ~$1.1B cumulative revenue through patent expiration in 2035
- Increasing disease incidence driven by tick range expansion and growing immunocompromised population

Seasoned Management Team and Board

- Profound clinical expertise in tafenoquine and related therapeutics
- Team has together led/managed six clinical trials
- Collectively led multiple pharmaceutical product approvals/ international pharmaceutical product launches
- Collectively led/provided guidance to multiple public & private entities
- Participated in/led multiple public listings

Buy rating from Ascendiant Capital Markets; $3 PT

Nasdaq: **SXTP**

Portfolio



Value Proposition

60P is addressing unmet medical needs in vector-borne disease through the development and commercialization of small-molecule therapeutics with established safety profiles. Building on its FDA-approved malaria prophylaxis ARAKODA® (tafenoquine), the Company is advancing tafenoquine into new indications, notably babesiosis, a rapidly growing tick-borne infection with no FDA-approved treatments.

In October 2025, 60P reported no Babesia infection detected in the first patient to complete therapy in its relapsing babesiosis study, an encouraging early signal supporting tafenoquine's potential to address this growing unmet need. The Company has submitted a Breakthrough Therapy Designation request and plans an FDA Type B meeting in early 2026 to define requirements for a supplementary New Drug Application (sNDA) expected in 2026.

Independent research estimates the U.S. babesiosis market at ~380,000 addressable patients annually, representing ~$245 million in peak yearly sales and ~$1.1 billion in cumulative revenue potential through 2035. Supported by its existing commercial infrastructure and seasoned leadership team, 60P offers investors a capital-efficient path to expansion and meaningful upside potential in a high-growth vector-borne disease market.

60P is also testing the viability of another product (Celgosivir) to determine whether to advance it into further clinical development and may seek to develop and license other molecules in the future.

About Babesiosis

- Tick-borne disease caused by protozoan parasites of the genus *Babesia*
- Invades red blood cells, causing:
  - Non-specific flu-like symptoms
  - Anemia
  - Death (1.6% mortality rate in hospitalized patients/10% in those with cardiac complications)
  - May be refractory to treatment in immunosuppressed patients
  - Associated with chronic post-treatment syndrome
- Common in Mid-West and Northeastern US
  - Geographic range expanding and incidence increasing
- Common coinfection with Lyme disease (10% of cases)